In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

AstraZeneca licenses CytoFab from Protherics for £195mm; terminated

Executive Summary

Protherics PLC (inflammation and cancer) has licensed AstraZeneca worldwide rights to develop and commercialize its CytoFab candidate that has completed Phase II development for severe sepsis.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Manufacturing or Supply
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register